See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Poseida Therapeutics, Inc. (PSTX) - free report >>
Cytokinetics, Incorporated (CYTK) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Poseida Therapeutics, Inc. (PSTX) - free report >>
Cytokinetics, Incorporated (CYTK) - free report >>
Image: Bigstock
New Strong Sell Stocks for August 27th
Here are five stocks added to the Zacks Rank #5 (Strong Sell) List today:
Cardlytics, Inc. (CDLX - Free Report) operates an advertising platform within financial institutions digital channels. The Zacks Consensus Estimate for its current year earnings has been revised 57.9% downward over the last 30 days.
Energy Fuels Inc. (UUUU - Free Report) engages in the extraction, recovery, exploration, and sale of conventional and in situ uranium recovery. The Zacks Consensus Estimate for its current year earnings has been revised 23.5% downward over the last 30 days.
Invacare Corporation designs, manufactures, distributes, and exports medical equipment for use in home health care, retail, and extended care markets. The Zacks Consensus Estimate for its current year earnings has been revised 11.5% downward over the last 30 days.
Poseida Therapeutics, Inc. (PSTX - Free Report) is a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The Zacks Consensus Estimate for its current year earnings has been revised 9.8% downward over the last 30 days.
Cytokinetics, Incorporated (CYTK - Free Report) is a late-stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 15.7% downward over the last 30 days.
View the entire Zacks Rank #5 List.